skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

This content will become publicly available on December 26, 2020

Title: Niacin for Parkinson's disease

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [7]
  1. Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Neuroscience Augusta University Augusta Georgia USA
  2. Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Undergraduate Health Professionals Augusta University Augusta Georgia USA
  3. Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Physical Therapy Augusta University Augusta Georgia USA
  4. Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Oral Biology and Diagnostic Sciences Augusta University Augusta Georgia USA
  5. Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Neurology Augusta University Augusta Georgia USA
  6. Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Interdisciplinary Health Sciences Augusta University Augusta Georgia USA
  7. Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Neuroscience Augusta University Augusta Georgia USA, Department of Physical Therapy Augusta University Augusta Georgia USA, Department of Neurology Augusta University Augusta Georgia USA
Publication Date:
Sponsoring Org.:
USDOE Office of Electricity Delivery and Energy Reliability (OE), Power Systems Engineering Research and Development (R&D) (OE-10)
OSTI Identifier:
1580552
Resource Type:
Publisher's Accepted Manuscript
Journal Name:
Clinical and Experimental Neuroimmunology
Additional Journal Information:
Journal Name: Clinical and Experimental Neuroimmunology; Journal ID: ISSN 1759-1961
Publisher:
Wiley-Blackwell
Country of Publication:
Country unknown/Code not available
Language:
English

Citation Formats

Seamon, Marissa, Purohit, Sharad, Giri, Banabihari, Baban, Babak, Morgan, John, Chong, Raymond, and Wakade, Chandramohan. Niacin for Parkinson's disease. Country unknown/Code not available: N. p., 2019. Web. doi:10.1111/cen3.12553.
Seamon, Marissa, Purohit, Sharad, Giri, Banabihari, Baban, Babak, Morgan, John, Chong, Raymond, & Wakade, Chandramohan. Niacin for Parkinson's disease. Country unknown/Code not available. doi:10.1111/cen3.12553.
Seamon, Marissa, Purohit, Sharad, Giri, Banabihari, Baban, Babak, Morgan, John, Chong, Raymond, and Wakade, Chandramohan. Fri . "Niacin for Parkinson's disease". Country unknown/Code not available. doi:10.1111/cen3.12553.
@article{osti_1580552,
title = {Niacin for Parkinson's disease},
author = {Seamon, Marissa and Purohit, Sharad and Giri, Banabihari and Baban, Babak and Morgan, John and Chong, Raymond and Wakade, Chandramohan},
abstractNote = {},
doi = {10.1111/cen3.12553},
journal = {Clinical and Experimental Neuroimmunology},
number = ,
volume = ,
place = {Country unknown/Code not available},
year = {2019},
month = {12}
}

Journal Article:
Free Publicly Available Full Text
This content will become publicly available on December 26, 2020
Publisher's Version of Record

Save / Share:

Works referenced in this record:

Nicotinamide Treatment Provides Acute Neuroprotection and GFAP Regulation following Fluid Percussion Injury
journal, February 2008

  • Holland, Michael A.; Tan, Arlene A.; Smith, Douglas C.
  • Journal of Neurotrauma, Vol. 25, Issue 2
  • DOI: 10.1089/neu.2007.0312

A novel treatment target for Parkinson's disease
journal, December 2014

  • Wakade, Chandramohan; Chong, Raymond
  • Journal of the Neurological Sciences, Vol. 347, Issue 1-2
  • DOI: 10.1016/j.jns.2014.10.024

Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis
journal, January 2014


Zolpidem improves akinesia, dystonia and dyskinesia in advanced Parkinson’s disease
journal, August 2008


Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease: Preladenant Long-Term Safety and Efficacy
journal, April 2013

  • Factor, Stewart A.; Wolski, Kenneth; Togasaki, Daniel M.
  • Movement Disorders, Vol. 28, Issue 6
  • DOI: 10.1002/mds.25395

Niacin modulates macrophage polarization in Parkinson's disease
journal, July 2018


Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent Mechanisms
journal, March 2012

  • Digby, Janet E.; Martinez, Fernando; Jefferson, Andrew
  • Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 32, Issue 3
  • DOI: 10.1161/ATVBAHA.111.241836

The Niacin/Butyrate Receptor GPR109A Suppresses Mammary Tumorigenesis by Inhibiting Cell Survival
journal, December 2013


Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
journal, March 2011

  • Lukasova, Martina; Malaval, Camille; Gille, Andreas
  • Journal of Clinical Investigation, Vol. 121, Issue 3
  • DOI: 10.1172/JCI41651

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
journal, January 2010


Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
journal, August 2016

  • Pagan, Fernando; Hebron, Michaeline; Valadez, Ellen H.
  • Journal of Parkinson's Disease, Vol. 6, Issue 3
  • DOI: 10.3233/JPD-160867

Microglial/Macrophage Polarization Dynamics following Traumatic Brain Injury
journal, October 2016

  • Kumar, Alok; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.
  • Journal of Neurotrauma, Vol. 33, Issue 19
  • DOI: 10.1089/neu.2015.4268

Zolpidem in Parkinson's disease
journal, April 1997


Zonisamide has beneficial effects on Parkinson's disease patients
journal, December 2001


Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of  -synuclein in Parkinson's disease models
journal, May 2013

  • Hebron, M. L.; Lonskaya, I.; Moussa, C. E. - H.
  • Human Molecular Genetics, Vol. 22, Issue 16
  • DOI: 10.1093/hmg/ddt192

Oral Exposure to Paraquat Triggers Earlier Expression of Phosphorylated α-Synuclein in the Enteric Nervous System of A53T Mutant Human α-Synuclein Transgenic Mice
journal, October 2017

  • Naudet, Nicolas; Antier, Emilie; Gaillard, Damien
  • Journal of Neuropathology & Experimental Neurology, Vol. 76, Issue 12
  • DOI: 10.1093/jnen/nlx092

Upregulation of GPR109A in Parkinson’s Disease
journal, October 2014


Oxidative stress in Parkinson's disease
journal, January 2003


The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic
journal, August 2003


GPR109A and Vascular Inflammation
journal, March 2013

  • Chai, Joshua T.; Digby, Janet E.; Choudhury, Robin P.
  • Current Atherosclerosis Reports, Vol. 15, Issue 5
  • DOI: 10.1007/s11883-013-0325-9

Lewy body diseases and multiple system atrophy as α-synucleinopathies
journal, November 1998


Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages
journal, October 2014

  • Feingold, Kenneth R.; Moser, Arthur; Shigenaga, Judy K.
  • Journal of Lipid Research, Vol. 55, Issue 12
  • DOI: 10.1194/jlr.M050955

Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results
journal, September 2012

  • Hasan, David; Chalouhi, Nohra; Jabbour, Pascal
  • Journal of Neuroinflammation, Vol. 9, Issue 1
  • DOI: 10.1186/1742-2094-9-222

Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress
journal, September 2017

  • Coles, Lisa D.; Tuite, Paul J.; Öz, Gülin
  • The Journal of Clinical Pharmacology, Vol. 58, Issue 2
  • DOI: 10.1002/jcph.1008

 -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
journal, May 1998

  • Spillantini, M. G.; Crowther, R. A.; Jakes, R.
  • Proceedings of the National Academy of Sciences, Vol. 95, Issue 11
  • DOI: 10.1073/pnas.95.11.6469

Low-dose niacin supplementation modulates GPR109A, niacin index and ameliorates Parkinson's disease symptoms without side effects
journal, June 2015

  • Wakade, Chandramohan; Chong, Raymond; Bradley, Eric
  • Clinical Case Reports, Vol. 3, Issue 7
  • DOI: 10.1002/ccr3.232

Interaction Among Mitochondria, Mitogen-Activated Protein Kinases, and Nuclear Factor-κB in Cellular Models of Parkinson's Disease
journal, April 2000


Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
journal, May 2009


PUMA-G, an IFN-γ-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily
journal, December 2001


Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-dependent, Ca 2+ -induced Mitochondrial Dysfunction
journal, June 2014

  • Luth, Eric S.; Stavrovskaya, Irina G.; Bartels, Tim
  • Journal of Biological Chemistry, Vol. 289, Issue 31
  • DOI: 10.1074/jbc.M113.545749

Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system
journal, June 2012

  • Hernández-Romero, Mª Carmen; Delgado-Cortés, Mª José; Sarmiento, Manuel
  • NeuroToxicology, Vol. 33, Issue 3
  • DOI: 10.1016/j.neuro.2012.01.018

Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts
journal, October 1997


Decreased Activity of 3-Hydroxybutyrate Dehydrogenase in Diabetic Liver Mitochondria
journal, July 1971

  • Roldan, A. G.; Del Castillo, E. J.; Boveris, A.
  • Experimental Biology and Medicine, Vol. 137, Issue 3
  • DOI: 10.3181/00379727-137-35668

Impairment of glutamate uptake and absence of alterations in the energy-transducing ability of old rat brain mitochondria
journal, March 1985

  • Vitorica, Javier; Clark, Arthur; Machado, Alberto
  • Mechanisms of Ageing and Development, Vol. 29, Issue 3
  • DOI: 10.1016/0047-6374(85)90066-1

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
journal, March 2019

  • Pagan, Fernando L.; Hebron, Michaeline L.; Wilmarth, Barbara
  • Pharmacology Research & Perspectives, Vol. 7, Issue 2
  • DOI: 10.1002/prp2.470

Oral butyrate for mildly to moderately active Crohn's disease
journal, November 2005


GPR109A (PUMA-G/HM74A) mediates nicotinic acid–induced flushing
journal, December 2005

  • Benyó, Zoltán; Gille, Andreas; Kero, Jukka
  • Journal of Clinical Investigation, Vol. 115, Issue 12
  • DOI: 10.1172/JCI23626

Levodopa-induced dyskinesias
journal, January 2007

  • Fabbrini, Giovanni; Brotchie, Jonathan M.; Grandas, Francisco
  • Movement Disorders, Vol. 22, Issue 10
  • DOI: 10.1002/mds.21475

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
journal, May 2017

  • Martin-Bastida, Antonio; Ward, Roberta J.; Newbould, Rexford
  • Scientific Reports, Vol. 7, Issue 1
  • DOI: 10.1038/s41598-017-01402-2

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
journal, January 2004

  • Stern, Matthew B.; Marek, Kenneth L.; Friedman, Joseph
  • Movement Disorders, Vol. 19, Issue 8
  • DOI: 10.1002/mds.20145

Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
journal, May 2017

  • Mischley, Laurie K.; Lau, Richard C.; Shankland, Eric G.
  • Journal of Parkinson's Disease, Vol. 7, Issue 2
  • DOI: 10.3233/JPD-161040

A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease: PHASE I/IIA (IN)GSH IN PD
journal, July 2015

  • Mischley, Laurie K.; Leverenz, James B.; Lau, Richard C.
  • Movement Disorders, Vol. 30, Issue 12
  • DOI: 10.1002/mds.26351

Treatment of Parkinson's Syndrome with L Dihydroxyphenylalanine (Levodopa)
journal, January 1970


Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis
journal, March 2010


Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
journal, July 2014

  • Aviles-Olmos, Iciar; Dickson, John; Kefalopoulou, Zinovia
  • Journal of Parkinson's Disease, Vol. 4, Issue 3
  • DOI: 10.3233/JPD-140364

GPR109A as an Anti-Inflammatory Receptor in Retinal Pigment Epithelial Cells and Its Relevance to Diabetic Retinopathy
journal, April 2012

  • Gambhir, Deeksha; Ananth, Sudha; Veeranan-Karmegam, Rajalakshmi
  • Investigative Opthalmology & Visual Science, Vol. 53, Issue 4
  • DOI: 10.1167/iovs.11-8447

Utilization of tryptophan, nicotinamide and nicotinic acid as precursors for nicotinamide nucleotide synthesis in isolated rat liver cells
journal, March 1988

  • Bender, David A.; Olufunwa, Ronald
  • British Journal of Nutrition, Vol. 59, Issue 2
  • DOI: 10.1079/BJN19880035

N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases
journal, January 2013


Mitochondrial Complex I Deficiency in Parkinson's Disease
journal, March 1990


Randomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PD
journal, August 2003


Niacin Depletion in Parkinsonian Patients Treated with L-dopa, Benserazide and Carbidopa
journal, January 1979

  • Bender, D. A.; Earl, C. J.; Lees, A. J.
  • Clinical Science, Vol. 56, Issue 1
  • DOI: 10.1042/cs0560089

Nitric oxide synthase and neuronal vulnerability in parkinson's disease
journal, May 1996


Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia
journal, November 2012


The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target
journal, July 2006


Ageing and Parkinson'S Disease: Substantia Nigra Regional Selectivity
journal, January 1991


Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease
journal, March 1992


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
journal, October 2017


Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial
journal, January 2006

  • Ondo, William G.; Silay, Yavuz S.
  • Movement Disorders, Vol. 21, Issue 10
  • DOI: 10.1002/mds.21022

A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease: protocol and baseline characteristics
journal, May 2016


Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD): Serum Immune Markers and PD Progression
journal, March 2016

  • Williams-Gray, Caroline H.; Wijeyekoon, Ruwani; Yarnall, Alison J.
  • Movement Disorders, Vol. 31, Issue 7
  • DOI: 10.1002/mds.26563

Mitochondrial function in Parkinson's disease
journal, January 1992

  • Schapira, Anthony H. V.; Mann, Vincent M.; Cooper, J. Mark
  • Annals of Neurology, Vol. 32, Issue S1
  • DOI: 10.1002/ana.410320720

Chronic systemic pesticide exposure reproduces features of Parkinson's disease
journal, December 2000

  • Betarbet, Ranjita; Sherer, Todd B.; MacKenzie, Gillian
  • Nature Neuroscience, Vol. 3, Issue 12
  • DOI: 10.1038/81834

Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid
journal, January 2003

  • Wise, Alan; Foord, Steven M.; Fraser, Neil J.
  • Journal of Biological Chemistry, Vol. 278, Issue 11
  • DOI: 10.1074/jbc.M210695200

Effects of rotenone and pyridaben on complex I electron transfer and on mitochondrial nitric oxide synthase functional activity
journal, October 2010

  • Navarro, Ana; Bández, Manuel J.; Gómez, Carmen
  • Journal of Bioenergetics and Biomembranes, Vol. 42, Issue 5
  • DOI: 10.1007/s10863-010-9309-4

Niacin Treatment of Stroke Increases Synaptic Plasticity and Axon Growth in Rats
journal, September 2010


Zonisamide: A new drug for Parkinson's disease
journal, January 2010


In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
journal, February 2006


In vivo demonstration that  -synuclein oligomers are toxic
journal, February 2011

  • Winner, B.; Jappelli, R.; Maji, S. K.
  • Proceedings of the National Academy of Sciences, Vol. 108, Issue 10
  • DOI: 10.1073/pnas.1100976108

Effects of Niacin Restriction on Sirtuin and PARP Responses to Photodamage in Human Skin
journal, July 2012


Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
journal, May 2017


Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
journal, March 2011


α-Synuclein Activates Microglia by Inducing the Expressions of Matrix Metalloproteinases and the Subsequent Activation of Protease-Activated Receptor-1
journal, May 2010

  • Lee, Eun-Jung; Woo, Moon-Sook; Moon, Pyong-Gon
  • The Journal of Immunology, Vol. 185, Issue 1
  • DOI: 10.4049/jimmunol.0903480

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
journal, July 2015

  • Jucaite, Aurelija; Svenningsson, Per; Rinne, Juha O.
  • Brain, Vol. 138, Issue 9
  • DOI: 10.1093/brain/awv184


journal, February 2004


Microglia and neurodegeneration: The role of systemic inflammation
journal, June 2012


Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
journal, May 2011

  • Collier, Timothy J.; Kanaan, Nicholas M.; Kordower, Jeffrey H.
  • Nature Reviews Neuroscience, Vol. 12, Issue 6
  • DOI: 10.1038/nrn3039

Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease: LETTERS: NEW OBSERVATIONS
journal, September 2018

  • Yoritaka, Asako; Ohtsuka, Chigumi; Maeda, Tetsuya
  • Movement Disorders, Vol. 33, Issue 9
  • DOI: 10.1002/mds.27472

Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
journal, April 2013


The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages
journal, May 2014

  • Rahman, Mahbubur; Muhammad, Sajjad; Khan, Mahtab A.
  • Nature Communications, Vol. 5, Issue 1
  • DOI: 10.1038/ncomms4944

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects
journal, August 1997

  • Shults, Clifford W.; Haas, Richard H.; Passov, David
  • Annals of Neurology, Vol. 42, Issue 2
  • DOI: 10.1002/ana.410420221

Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease
journal, August 2019


MDS clinical diagnostic criteria for Parkinson's disease: MDS-PD Clinical Diagnostic Criteria
journal, October 2015

  • Postuma, Ronald B.; Berg, Daniela; Stern, Matthew
  • Movement Disorders, Vol. 30, Issue 12
  • DOI: 10.1002/mds.26424

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease: Randomized Trial of P2B001 in Early PD
journal, April 2017

  • Olanow, C. Warren; Kieburtz, Karl; Leinonen, Mika
  • Movement Disorders, Vol. 32, Issue 5
  • DOI: 10.1002/mds.26941

Prevalence of Parkinson’s disease across North America
journal, July 2018


Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
journal, September 2014

  • Chagas, Marcos Hortes N.; Zuardi, Antonio W.; Tumas, Vitor
  • Journal of Psychopharmacology, Vol. 28, Issue 11
  • DOI: 10.1177/0269881114550355

Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
journal, January 2019

  • Verschuur, Constant V. M.; Suwijn, Sven R.; Boel, Judith A.
  • New England Journal of Medicine, Vol. 380, Issue 4
  • DOI: 10.1056/NEJMoa1809983

Oxidative damage to macromolecules in human Parkinson disease and the rotenone model
journal, September 2013


Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109A (HM74A/PUMA-G)
journal, August 2005

  • Tunaru, Sorin; Lättig, Jens; Kero, Jukka
  • Molecular Pharmacology, Vol. 68, Issue 5
  • DOI: 10.1124/mol.105.015750

Zonisamide in patients with essential tremor and Parkinson's disease
journal, October 2007


Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice
journal, January 2010


The genetics of Parkinson disease
journal, March 2018


Evidence of Inflammatory System Involvement in Parkinson’s Disease
journal, January 2014

  • Chao, Yinxia; Wong, Siew Cheng; Tan, Eng King
  • BioMed Research International, Vol. 2014
  • DOI: 10.1155/2014/308654

α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
journal, November 2017

  • Harms, Ashley S.; Delic, Vedad; Thome, Aaron D.
  • Acta Neuropathologica Communications, Vol. 5, Issue 1
  • DOI: 10.1186/s40478-017-0494-9

Variation in Chronic Nicotinamide Treatment after Traumatic Brain Injury Can Alter Components of Functional Recovery Independent of Histological Damage
journal, January 2008

  • Hoane, Michael R.; Pierce, Jeremy L.; Kaufman, Nicholas A.
  • Oxidative Medicine and Cellular Longevity, Vol. 1, Issue 1
  • DOI: 10.4161/oxim.1.1.6694

Niaspan treatment induces neuroprotection after stroke
journal, October 2010


Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease: Glutathione in Parkinson's Disease
journal, February 2009

  • Hauser, Robert A.; Lyons, Kelly E.; McClain, Terry
  • Movement Disorders, Vol. 24, Issue 7
  • DOI: 10.1002/mds.22401

Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
journal, October 2012


Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology
journal, October 2009


Flumazenil, a GABA antagonist, may improve features of Parkinson's disease
journal, February 2003

  • Ondo, William G.; Hunter, Christine
  • Movement Disorders, Vol. 18, Issue 6
  • DOI: 10.1002/mds.10426

Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis
journal, August 2017


Levodopa: Is toxicity a myth?
journal, April 1998


Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience
journal, April 2017